• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

危重病患者中急性早幼粒细胞白血病早期死亡的分析。

Analysis of early death in critically ill patients with acute promyelocytic leukaemia in the HICU.

机构信息

Harbin Medical University, No. 157 Health Road, Nangang District, Harbin, 150001, China.

Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.

出版信息

Sci Rep. 2024 Aug 28;14(1):19987. doi: 10.1038/s41598-024-71082-2.

DOI:10.1038/s41598-024-71082-2
PMID:39198685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11358486/
Abstract

This study was conducted to identify the characteristics and risk factors for early death in critically ill acute promyelocytic leukaemia (APL) patients in the Hemato-oncology ICU (HICU). A total of 44 APL patients from 2017 to 2023 were included. The mortality among APL patients in the HICU was high (27/44, 61.36%). Compared with patients who survived, nonsurvivors had a longer prothrombin time (P = 0.002), lower fibrinogen (P = 0.022), higher white blood cell count (P = 0.004) and higher creatinine (P = 0.037) on hosipital admission. Severe bleeding was the most frequent complication (34 cases, 77.27%), which occurred either preinduction or on Day 5 (IQR 3-7.5 days) of induction. Cerebral bleeding associated with consciousness disturbance was the main reason for HICU admission (18 cases, 40.9%). The leading cause of death was fatal haemorrhage (18/34, 52.94%), which occurred either preinduction or on Day 4 (IQR 3-7 days) of induction. Another common cause of death was sepsis (8/18, 44.44%), which occurred on Day 12 (IQR 9.5-24.75 days) during induction. In conclusion, the main cause of death in APL patients treated in the HICU was primary being attributed to fatal bleeding, followed by sepsis.

摘要

本研究旨在确定重症监护病房(HICU)中急性早幼粒细胞白血病(APL)危重症患者早期死亡的特征和危险因素。共纳入 2017 年至 2023 年的 44 例 APL 患者。APL 患者在 HICU 中的死亡率很高(27/44,61.36%)。与存活患者相比,非存活患者的凝血酶原时间更长(P=0.002),纤维蛋白原更低(P=0.022),白细胞计数更高(P=0.004),入院时肌酐更高(P=0.037)。严重出血是最常见的并发症(34 例,77.27%),发生在诱导前或诱导第 5 天(IQR 3-7.5 天)。与意识障碍相关的脑出血是 HICU 入院的主要原因(18 例,40.9%)。死亡的主要原因是致命性出血(18/34,52.94%),发生在诱导前或诱导第 4 天(IQR 3-7 天)。另一个常见的死亡原因是感染性休克(8/18,44.44%),发生在诱导第 12 天(IQR 9.5-24.75 天)。总之,HICU 中 APL 患者死亡的主要原因是致命性出血,其次是感染性休克。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86db/11358486/a0ee6908ed25/41598_2024_71082_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86db/11358486/0bc0029c8760/41598_2024_71082_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86db/11358486/10e900927f65/41598_2024_71082_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86db/11358486/a0ee6908ed25/41598_2024_71082_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86db/11358486/0bc0029c8760/41598_2024_71082_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86db/11358486/10e900927f65/41598_2024_71082_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86db/11358486/a0ee6908ed25/41598_2024_71082_Fig3_HTML.jpg

相似文献

1
Analysis of early death in critically ill patients with acute promyelocytic leukaemia in the HICU.危重病患者中急性早幼粒细胞白血病早期死亡的分析。
Sci Rep. 2024 Aug 28;14(1):19987. doi: 10.1038/s41598-024-71082-2.
2
Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone.三氧化二砷单独治疗急性早幼粒细胞白血病患者血栓出血性早期死亡的影响因素。
Blood Cells Mol Dis. 2019 Nov;79:102351. doi: 10.1016/j.bcmd.2019.102351. Epub 2019 Aug 1.
3
Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials.未纳入临床试验的急性早幼粒细胞白血病(APL)患者的管理和治疗结果。
Eur J Cancer. 2014 Apr;50(6):1159-68. doi: 10.1016/j.ejca.2013.11.023. Epub 2014 Jan 15.
4
[Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].[全反式维甲酸对新诊断急性早幼粒细胞白血病的疗效:我们的经验]
Srp Arh Celok Lek. 1995 Nov-Dec;123(11-12):279-85.
5
Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.急性早幼粒细胞白血病诱导缓解期间使用或不使用全反式维甲酸时的早期出血性发病率和死亡率
Br J Haematol. 2000 Mar;108(4):689-95. doi: 10.1046/j.1365-2141.2000.01936.x.
6
Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.急性早幼粒细胞白血病的持续高早期死亡率:来自瑞典成人急性白血病登记处的一项基于人群的报告。
Leukemia. 2011 Jul;25(7):1128-34. doi: 10.1038/leu.2011.78. Epub 2011 Apr 19.
7
Acute promyelocytic leukemia is a distinct subset of acute myelocytic leukemia with unique clinicopathologic characteristics including longer duration of relapse free survival: experience in 13 cases.急性早幼粒细胞白血病是急性髓细胞白血病的一个独特亚型,具有独特的临床病理特征,包括无复发生存期较长:13例经验。
J Korean Med Sci. 1994 Dec;9(6):437-43. doi: 10.3346/jkms.1994.9.6.437.
8
Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia.日本急性早幼粒细胞白血病患者早期死亡、严重出血和分化综合征的预测因素。
Ann Hematol. 2020 Dec;99(12):2787-2800. doi: 10.1007/s00277-020-04245-6. Epub 2020 Sep 2.
9
Predictors of early hemorrhage in acute promyelocytic leukemia.急性早幼粒细胞白血病早期出血的预测因素。
Leuk Lymphoma. 2019 Oct;60(10):2394-2403. doi: 10.1080/10428194.2019.1581187. Epub 2019 Mar 8.
10
Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.单用三氧化二砷治疗的急性早幼粒细胞白血病患者早期死亡的基因突变。
Clin Transl Oncol. 2021 Oct;23(10):2171-2180. doi: 10.1007/s12094-021-02625-6. Epub 2021 May 3.

引用本文的文献

1
Induction treatments with and without addition of one dose anthracycline to all-trans retinoid acid and arsenic in pediatric non-high-risk acute promyelocytic leukemia: study protocol for a randomized controlled trial.在儿童非高危急性早幼粒细胞白血病中,全反式维甲酸和砷剂治疗基础上添加或不添加一剂蒽环类药物的诱导治疗:一项随机对照试验的研究方案
Trials. 2024 Dec 18;25(1):819. doi: 10.1186/s13063-024-08664-y.

本文引用的文献

1
Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy.急性早幼粒细胞白血病:全反式维甲酸和三氧化二砷治疗相关并发症综述
Cancers (Basel). 2024 Mar 15;16(6):1160. doi: 10.3390/cancers16061160.
2
Complications during Induction Chemotherapy in Acute Promyelocytic Leukemia: An Institutional Experience.急性早幼粒细胞白血病诱导化疗期间的并发症:一项机构经验
South Asian J Cancer. 2022 Nov 2;12(3):274-279. doi: 10.1055/s-0042-1757303. eCollection 2023 Jul.
3
Early Death and Survival of Patients With Acute Promyelocytic Leukemia in ATRA Plus Arsenic Era: A Population-Based Study.
全反式维甲酸联合砷剂时代急性早幼粒细胞白血病患者的早期死亡与生存:一项基于人群的研究
Front Oncol. 2021 Nov 16;11:762653. doi: 10.3389/fonc.2021.762653. eCollection 2021.
4
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.拯救脓毒症运动:2021年脓毒症和脓毒性休克国际管理指南
Crit Care Med. 2021 Nov 1;49(11):e1063-e1143. doi: 10.1097/CCM.0000000000005337.
5
Outcomes for Patients With Acute Promyelocytic Leukemia in South Africa.南非急性早幼粒细胞白血病患者的预后。
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e348-e352. doi: 10.1016/j.clml.2020.12.006. Epub 2020 Dec 11.
6
Acute promyelocytic leukemia (APL): a review of the literature.急性早幼粒细胞白血病(APL):文献综述
Oncotarget. 2020 Mar 17;11(11):992-1003. doi: 10.18632/oncotarget.27513.
7
Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.急性早幼粒细胞白血病(APL):实现全面治愈面临的尚存挑战。
Leuk Lymphoma. 2019 Dec;60(13):3107-3115. doi: 10.1080/10428194.2019.1613540. Epub 2019 Dec 16.
8
The Factors Affecting Early Death in Newly Diagnosed APL Patients.新诊断的急性早幼粒细胞白血病患者早期死亡的影响因素
Open Med (Wars). 2019 Sep 12;14:647-652. doi: 10.1515/med-2019-0074. eCollection 2019.
9
Acute promyelocytic leukemia in the intensive care unit: A retrospective analysis.
Leuk Res. 2018 Oct;73:41-43. doi: 10.1016/j.leukres.2018.08.004. Epub 2018 Aug 31.
10
Analysis of early death in newly diagnosed acute promyelocytic leukemia patients.新诊断急性早幼粒细胞白血病患者早期死亡情况分析
Medicine (Baltimore). 2017 Dec;96(51):e9324. doi: 10.1097/MD.0000000000009324.